MIND is advancing scalable psychedelic therapies for treatment-resistant CNS disorders, delivering more durable efficacy with fewer side effects while reducing the operational complexity of existing treatment models
Pipeline
Indication
Asset
Preclinical
Phase I
Phase 2A
Phase 2B
Phase 3
Treatment Resistant Depression
MIND001
Treatment Resistant Depression - MIND001
Migraine Prevention
MIND002
Migraine Prevention - MIND002
Cluster Headache Prevention
MIND002
Cluster Headache Prevention - MIND002
MIND001
Intravenous formulation of N,N-Dimethyltrptamine to treat Treatment Resistant Depression
MIND002
Oral Psilocybin formulation to treat headache disorders- Migraine and Cluster Headaches
With N = 36 completed and N > 100 in progress, early data show promising differentiation across safety, efficacy, dosing, and monitoring. Reduced psychedelic trip burden, minimal monitoring, and no psychotherapy requirement support a highly scalable care model vs existing treatment options.